Zacks Research Has Bearish Forecast for BAX Q3 Earnings

Baxter International Inc. (NYSE:BAX) – Equities researchers at Zacks Research decreased their Q3 2025 earnings per share estimates for shares of Baxter International in a research note issued to investors on Thursday, May 22nd. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of $0.63 for the quarter, down from their previous estimate of $0.66. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q2 2026 earnings at $0.61 EPS, Q4 2026 earnings at $0.77 EPS and Q1 2027 earnings at $0.57 EPS.

BAX has been the topic of a number of other research reports. Argus raised shares of Baxter International from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. JPMorgan Chase & Co. cut their price objective on Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a research report on Friday, February 21st. The Goldman Sachs Group started coverage on Baxter International in a research report on Wednesday, February 26th. They issued a “buy” rating and a $42.00 target price for the company. Wells Fargo & Company lowered their target price on Baxter International from $36.00 to $33.00 and set an “equal weight” rating for the company in a research note on Friday, May 2nd. Finally, Morgan Stanley reduced their price target on Baxter International from $30.00 to $28.00 and set an “underweight” rating on the stock in a research report on Monday, May 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $37.25.

Baxter International Trading Down 0.4%

NYSE BAX opened at $30.16 on Monday. The firm has a market capitalization of $15.48 billion, a price-to-earnings ratio of -23.56, a PEG ratio of 0.93 and a beta of 0.63. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. Baxter International has a one year low of $26.25 and a one year high of $40.49. The company’s 50 day moving average price is $30.78 and its 200 day moving average price is $31.60.

Baxter International (NYSE:BAX) last released its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.14. The company had revenue of $2.63 billion for the quarter, compared to the consensus estimate of $2.59 billion. Baxter International had a positive return on equity of 16.67% and a negative net margin of 5.05%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $0.65 EPS.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BAX. Dodge & Cox grew its stake in Baxter International by 2.1% in the first quarter. Dodge & Cox now owns 51,458,925 shares of the medical instruments supplier’s stock worth $1,761,439,000 after purchasing an additional 1,081,631 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Baxter International by 22.3% during the 4th quarter. Bank of New York Mellon Corp now owns 15,359,040 shares of the medical instruments supplier’s stock worth $447,870,000 after buying an additional 2,803,920 shares during the last quarter. Geode Capital Management LLC lifted its holdings in Baxter International by 2.4% during the 4th quarter. Geode Capital Management LLC now owns 12,446,939 shares of the medical instruments supplier’s stock worth $362,006,000 after buying an additional 290,279 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in shares of Baxter International by 1.1% in the 1st quarter. Ameriprise Financial Inc. now owns 7,540,942 shares of the medical instruments supplier’s stock valued at $258,140,000 after acquiring an additional 83,973 shares during the last quarter. Finally, Sound Shore Management Inc. CT raised its position in shares of Baxter International by 13.7% during the 1st quarter. Sound Shore Management Inc. CT now owns 2,825,902 shares of the medical instruments supplier’s stock valued at $96,731,000 after acquiring an additional 341,321 shares in the last quarter. 90.19% of the stock is owned by institutional investors and hedge funds.

Baxter International Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Friday, May 30th will be paid a $0.17 dividend. The ex-dividend date is Friday, May 30th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.25%. Baxter International’s dividend payout ratio (DPR) is presently -61.82%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.